

# **MAV+ Overview**

Last updated: April 2025

# The challenge

Every year, over 10 million people, primarily in low- and middle-income countries (LMICs), die needlessly due to lack of access to essential medicines. In 2011, a HAI/WHO report revealed that over half of Africa's population lacks access to essential medicines due to availability issues, and in 2015 alone, approximately 1.6 million Africans died from diseases that are preventable or treatable with timely access to health products such as malaria, tuberculosis and HIV-related illnesses.

Africa currently imports over 99% of the vaccines and 94% of the medicines it uses. As the COVID-19 pandemic made clear, this dependence on imports contributes to inequitable access to health products and to adverse health outcomes.

# The response

In response to the call from African leaders to produce 60% of vaccines in Africa by 2040, the Team Europe Initiative on Manufacturing and Access to Vaccines, Medicines and Health Technologies in Africa (MAV+) was launched in 2021.

MAV+ is a comprehensive support package tackling barriers to manufacturing and access to health products and technologies in Africa that is tightly aligned with African strategies and priorities.

# The objective of MAV+

The overall objective of MAV+ is to facilitate access to quality, safe, effective and affordable health products as outlined in the UN's Sustainable Development Goal Target 3.8







# The Team Europe approach

Team Europe is a broad and inclusive consortium of European actors, including the European Commission, EU Member States, the European Investment Bank, the European Medicines Agency, development agencies, top-ranking universities, dynamic research centres and an active, independent private sector, including biotech and pharma companies.

MAV+ focuses on:

#### 3 dimensions:

- Supply
- Demand
- Enabling environment

#### **Across 6 workstreams:**

- Industrial development, supply chains and private sector
- Market shaping, demand, and trade facilitation
- Regulatory strengthening
- Technology transfer and intellectual property management
- Access to finance
- R&D, higher education, and skills

MAV+ is aligned with the EU's Global Health Strategy and Global Gateway strategy as well as the Framework for Action from the Africa CDC's Platform for Harmonized African Health Products Manufacturing, and it complements other Team Europe Initiatives working on health and social protection in Africa.

# **Team Europe funders**

MAV+ is funded by the European Commission, Belgium, France, Germany, Luxembourg, The Netherlands, Spain, Sweden and the European Investment Bank.

## **Partners**

MAV+ partners include African Union agencies (e.g., Africa CDC, AUDA-NEPAD), African Union Member State National Regulatory Authorities, Regional Economic Communities, African universities and training programs and pharmaceutical manufacturing plants.

# Additional Team Europe and international stakeholders

AFD, Afreximbank, Africa CDC, Akagera Medicines Ltd, AMRH, AUDA-NEPAD, BfArM, BIO (Belgian Investment Company for Developing Countries) Biovac, Consortium, DEG, DEK, DKT International, DNDi, EIB, EC, EMA, Emzor Pharmaceutical, Industries Ltd, Enabel, Expertise France, GAVI, GIZ, IFC, International Centre for Genetic Engineering and Biotechnology, IoMT, GIZ, ITC, KfW, Kina Foundation, Ministry of Health of Senegal, MPP, National Vaccine Institute (NVI), NIPRD - National Institute of Pharmaceutical, Research and Development, NRA, PEI, Proparco, PTB, SIDA, UNECA, UNICEF, UNIDO, WHO and Women scientists and African Scientific Institutions.



# **Key activities**

## Continental highlights

- Support to Africa CDC's Platform for Harmonized African Health Products Manufacturing (PHAHM) with embedded experts
- Support to the operationalization of the African Medicines Agency (AMA) through twinning with European Medicines Agency (EMA), embedded experts and funding to AUDA-NEPAD (the
- Africa Union development agency) and WHO Establishment of an mRNA technology transfer programme with a hub in South Africa
- Product development partnerships and clinical trials grants, through EDCTP and other funding sources

# **Country highlights**

#### Senegal

Support of the MADIBA and Africamaril vaccine production projects, support to the coordination of the national plan for the pharmaceutical sector with the Ministry of Health and strengthening the new regulatory agency

## Ghana

Setting up of a local vaccine production site (DEK) and FDA strengthening for vaccine oversight

## **Egypt**

Support for research and development and regulatory strengthening

#### Rwanda

Support the enabling environment for the launch of an mRNA vaccine factory, strengthening Rwanda FDA through twinning with European counterparts, support for a new master's degree in biotechnology at University of Rwanda, skills development (including in TVET for the pharmaceutical sector) and support to SMEs

## **Nigeria**

Support the production of pharmaceutical ingredients, technical assistance to the government and digitalisation in the supply chain and regulatory functions

### **South Africa**

Support to Biovac and Aspen, funding fundamental and clinical research, supporting the digitalization in production facilities and supply chain and providing technical assistance on the establishment of the new National Regulatory Agency



# **Annex: MAV+ Project List**

Last updated: April 2025

The summary below includes all projects identified as of February 2025. For more detail on continental, regional, and country-level strategies and activities, please visit the <a href="Mailto:Capacity4Development project page">Capacity4Development project page</a>.

Note: For ease of review, complementary projects with the same institutions have been combined into a single row.

## **Continental**

- Support to Africa CDC's Platform for Harmonized African Health Products Manufacturing (PHAHM) with particular focus on talent development, market-shaping, and access to finance
- Strengthen the regulatory environment through support to the operationalization of the African Medicines Agency (AMA)
- Support R&D and promote technology transfer

Project title	Dimension	Partners	Funders
Contribution to GAVI's AVMA (African Vaccine Manufacturing Accelerator)	Demand	Gavi	EU, France, Germany
Strengthening vaccine and pharmaceutical value chain International Trade Center Regional Value Chain project	Demand	AfCFTA Secretariat, African Union, Africa EU partnership, ITC	EU
CLOSED: <u>Market shaping study on African</u> <u>Continental Free Trade Area (AfCFTA)</u>	Demand	UNECA (United Nations Economic Commission for Africa), French Development Agency - AFD	France
<u>Team Europe Support Structure for the</u> <u>TEI MAV+ (TESS MAV+)</u>	Demand Enabling environment	Africa CDC, AUDA-NEPAD, Enabel, GIZ, Expertise France	EU, Belgium, Germany
Global Program BACKUP Health	Demand Enabling environment	Africa CDC, African manufacturers, WHO, AVMI, Medicines Patent Pool, Wits University, RCORE Ghana, AMRH programme (AUDA-NEPAD), Ghana Food and Drugs Authority, GIZ	Germany





Project title	Dimension	Partners	Funders
Support to WHO's REG-unit for GBT- benchmarking and regulatory strengthening at regional level and prequalification	Enabling environment	National regulatory authorities, WHO	Belgium
Support to the operationalization of the African Medicines Agency (AMA) through AUDA-NEPAD (AMRH)	Enabling environment	AUDA-NEPAD, AMA, national regulatory authorities, AMRH programme (AUDA-NEPAD), Physi kalisch-Technische Bundesanstalt (PTB)	EU, Belgium, Germany
Support to the operationalization of the African Medicines Agency (AMA) through EMA-AMA twinning	Enabling environment	AUDA-NEPAD, African Medicines Agency (AMA), European Medicines Agency (EMA)	EU
Product Development Partnerships (PDP) II and III	Enabling environment	Drugs for Neglected Diseases initiative (DNDi), Foundation for Innovative New Diagnostics (FIND), International Partnerships for Microbicides (IPM), Medicines for Malaria Venture (MMV), PATH TB Alliance, PATH (Program for Appropriate Technology in Health), IAV (International AIDS Vaccine Initiative), EVI (European Vaccine Initiative), KfW	Germany
Technical assistance WHO-AFRO	Enabling environment	WHO, Expertise France	France
Monitoring and evaluation expert - Africa CDC	Enabling environment	Africa CDC	France
CLOSED: Technical assistance to the European Commission for supporting the TEI MAV+	Enabling environment	European Commission, Expertise France	France
CLOSED: <u>Support the research and</u> development of treatments for neglected <u>tropical diseases</u>	Enabling environment	Drugs for Neglected Diseases Initiative (DNDi)	France





Project title	Dimension	Partners	Funders
CLOSED: Expansion of the African Quality Infrastructure in the pharmaceutical and healthcare sector	Enabling environment	African Medicines Agency (AMA), national regulatory authorities, AUDA-NEPAD, African Organization for Standardization (ASO), Physikalisch-Technische Bundesanstalt (PTB)	Germany
CLOSED: WHO support to Local manufacturing and access to vaccines, medicines and health technologies in Africa (other than mRNA Tech Transfer)	Enabling environment	National regulatory authorities, WHO (via Medicines Patent Pool)	EU
CLOSED: Support to WHO on fair pricing, essential medicines and diagnostics lists, access to controlled medicines	Enabling environment	WHO	Belgium





- Support to regional local production in Southern Africa
- Capacity-building and training in supply, distribution and management in East, Central and West Africa
- Regional regulatory strengthening and harmonization across Africa

Project title	Dimension	Country / Region	Partners	Funders
Regional Center of Excellence for Vaccines, Immunization, and Health Supply Chain Management at University of Rwanda	Demand Enabling environment	East African Community (EAC)	Regional Center of Excellence at University of Rwanda Secretariat of the East African Community (EAC), KfW	Germany
Support to the EAC Integration Process	Enabling environment	East African Community (EAC)	Secretariat of the East African Community (EAC), GIZ	Germany
CLOSED: <u>SIPS – Support</u> <u>towards Industrialization</u> <u>and the Productive Sectors</u> <u>in the SADC Region</u>	Demand Enabling environment Supply	Southern African Development Community (SADC)	Southern African Development Community (SADC), Witwatersrand University, GIZ	EU, Germany
<u>REG-Pharma</u>	Enabling environment	West and Central Africa	WAHO (West African Health Organization), Expertise France	France
CLOSED: OCEAC Initiative	Enabling environment	Economic and Monetary Community of Central African States (CEMAC)	CEMAC, Expertise France	France



### **Key MAV+ priorities**

• Regional regulatory strengthening and harmonization across Africa

Project title	Dimension	Country / Region	Partners	Funders
MEDISAFE I and II: Falsified and substandard medicines	Enabling environment	Phase I: Burundi, Demographic Republic of Congo, Ethiopia, Ghana, Kenya, Malawi, Rwanda, Seychelles, Tanzania, Uganda and Zambia  Phase II: Benin, Cameroon, Côte d'Ivoire, Ghana, Republic of Guinea (Conakry), Nigeria, Senegal, Togo, Burundi, DRC, Ethiopia, Kenya, Rwanda, Zambia	EAC, AUDA-NEPAD, West and Eastern Africa (WEA), Expertise France, Initiative on Chemical, Biological, Radiological and Nuclear (CBRN) Risk Mitigation Centres of Excellence (CoE), The ASST Fatebenefratelli Sacco (SACCO), The Humanitarian Center for Pharmacy Trades (CHMP), The Professional Association of Public Pharmacy Inspectors (APROPHISP), The Network for Medicines and Development (ReMed), WHO, Interpol, UNODC, UNICRI, IGAD	EU
LabTrain: Strengthening Capacity and Structure Building in Drug Quality Assurance in African Countries – A contribution of BfArM to WHO Standards and Good Laboratory Practice	Enabling environment	Ghana, Liberia, Sierra Leone, The Gambia	WHO, Institut für pharmazeutische und angewandte Analytik (InphA), Universität Würzburg (JMU), Institut für Pharmazie und Lebensmittelchemie, Ghana Food and Drugs Authority, Liberia Medicines and Health Products Regulatory Authority (LMHRA), Pharmacy Board of Sierra Leone (PBSL), Medicines Control Agency (MCA) of The Gambia, German Federal Insitute for Drugs and Medical Devices (BfArM), German Federal Ministry of Health (BMG)	Germany





Project title	Dimension	Country / Region	Partners	Funders
VaccTrain2.0: Building regulatory capacity in vaccines - Training and scientific advice for the establishment of federal batch testing	Enabling environment	Ghana, Liberia, Sierra Leone, The Gambia, Zimbabwe, additional countries in Sub-Saharan Africa	Food and Drugs Authority (FDA), Ghana, Liberia Medicines and Health Products Regulatory Authority (LMHRA), Medicines Control Agency (MCA) of The Gambia, Pharmacy Board of Sierra Leone (PBSL), Medicines Control Authority of Zimbabwe (MCAZ), Rwanda Food and Drugs Authority (FDA), Agence sénégalaise de Réglementation pharmaceutique (ARP), South African Health Products Regulatory Authority (SAHPRA), AMRH programme (AUDANEPAD) and its specialised committees, African Vaccine Regulatory Forum (AVAREF), WHO/AFRO	Germany
PharmTrain (2) Building Regulatory Capacities and Structures: Marketing authorization of Medical Products	Enabling environment	Ghana, Liberia, Zimbabwe, Sierra Leone, Tanzania, The Gambia, South Africa	AUDA-NEPAD, Ghana Food and Drugs Authority, Liberia Medicines and Health Products Regulatory Authority (LMHRA), Medicines Control Agency (MCA) of The Gambia, Medicines Control Authority of Zimbabwe (MCAZ), Pharmacy Board of Sierra Leone (PBSL), South African Health Products Regulatory Authority (SAHPRA), Tanzania Medicines and Medical Devices Authority (TMDA), WHO, German Federal Insitute for Drugs and Medical Devices (BfArM), German Federal Ministry of Health (BMG)	Germany





Project title	Dimension	Country / Region	Partners	Funders
Increasing African production of vaccines and essential medicines through business linkages and technology transfer	Enabling environment	Nigeria, Ethiopia, Kenya, Tanzania, EAC, ECOWAS	ECOWAS and EAC Secretariats, WAHO, UNIDO	Germany
VaccRelease: Building regulatory capacity in vaccines - Training and scientific advice for the establishment of federal batch testing	Enabling environment	Ghana, Senegal, Rwanda, South Africa, ECOWAS, EAC, SADC	Ghana Food and Drugs Authority, Rwanda Food and Drug Authority, Agence sénégalaise de Réglementation pharmaceutique (ARP), South African Health Products Regulatory Authority (SAHPRA), South African National Control Laboratory for Biological Products (SANCLBP), AMRH programme (AUDA-NEPAD), African Medicines Quality Forum (AMQF), Physikalisch- Technische Bundesanstalt (PTB), GIZ, Paul-Ehrlich-Institut (PEI)	Germany
<u>DeveloPPP: Local</u> <u>manufacturing plant</u> <u>improves medical care</u>	Enabling environment Supply	Ghana, Tanzania, South Africa	DEK Consortium, Action medeor International Healthcare, Aspen, Siemens, DEG (German Investment Corporation)	Germany
CLOSED: <u>GHPP-PharmTrain:</u> <u>Regulatory training and</u> <u>advice in the field of</u> <u>Pharmaceutics</u>	Enabling environment	Ghana, Liberia, Zimbabwe, Sierra Leone, Tanzania, The Gambia	Ghana Food and Drugs Authority, Liberia Medicines and Health Products Regulatory Authority (LMHRA), Pharmacy Board Sierra Leone (PBSL), Medicines Control Agency (MCA) of The Gambia, Medicines Control Authority of Zimbabwe (MCAZ), Tanzania Medicines and Medical Devices Agency (TMDA), Paul-Ehrlich-Institut (PEI), German Federal Insitute for Drugs and Medical Devices (BfArM)	Germany



Project title	Dimension	Country / Region	Partners	Funders
CLOSED: Cooperation to strengthen laboratory quality assurance	Enabling environment	Benin, Burkina Faso, Niger Mauritania	National regulatory authorities in partner countries, Expertise France	France
CLOSED: PharmTrain CG -  Development of a  framework for the Regional  Implementation of a Risk- based Procedure for the  Evaluation of Unapproved  Drugs (WHO-EUL) for  Southern Africa	Enabling environment	Angola, Botswana, Comoros, Lesotho, Madagascar, Namibia, South Africa, Tanzania, Zambia, Zimbabwe	SADC, German Federal Institute for Drugs and Medical Devices (BfArM), German Federal Ministry of Health (BMG)	Germany
CLOSED: <u>RegTrain-</u> <u>VaccTrain: Regulatory</u> <u>Training and Advice in the</u> <u>Field of Vaccines and</u> <u>Biomedical Therapeutics</u>	Enabling environment	Ghana, Zimbabwe, Sierra Leone, The Gambia, Liberia	National regulatory authorities in the partner countries, Ghana Food and Drugs Authority, Liberia Medicines & Health Products Regulatory Authority (LMHRA), Pharmacy Board of Sierra Leone (PBSL), Medicines Control Agency (MCA) of The Gambia, Medicines Control Authority of Zimbabwe (MCAZ), AUDA-NEPAD, African Vaccine Regulatory Forum (AVAREF), German Federal Institute for Drugs and Medical Devices (BfArM), WHO, Paul-Ehrlich-Institut (PEI)	Germany







Project title	Dimension	Country / Region	Partners	Funders
CLOSED: <u>Support for the</u> <u>creation of an ACAME</u> <u>Training and Expertise</u> <u>Centre (CFEA)</u>	Enabling environment	Algeria, Benin, Burkina Faso, Burundi, Cameroon, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Djibouti, Gabon, Guinea, Guinea Bissau, Madagascar, Mali, Mauritania, Niger, Democratic Republic of Congo, Senegal, Togo, Tunisia	ACAME (African Association of Central Purchasing Centers for Essential Medicines), Expertise France	France
CLOSED: <u>Training African</u> <u>National Drug Quality</u> <u>Control Laboratories in</u> <u>Quality Assurance and</u> <u>Quality Management in the</u> <u>Context of Combating</u> <u>Antimicrobial Resistance</u> <u>(DQA)</u>	Enabling environment	Armenia, Botswana, Burkina Faso, Burundi, Cameroon, Egypt, Ethiopia, Ghana, Kenya, Malawi, Namibia, Nigeria, Rwanda, Senegal, Sierra Leone, The Gambia, Uganda, Zambia, Zimbabwe, Tanzania	National regulatory authorities and their quality control laboratories (NDQCLs) in the project partner countries, WHO – Regulation and Safety, Institute for Pharmaceutical and Applied Analytics (InphA), German Federal Insitute for Drugs and Medical Devices (BfArM), German Federal Ministry of Health (BMG)	Germany
CLOSED: <u>Investment into</u> <u>Goodlife Pharmacy, a</u> <u>network of pharmacies</u>	Supply	Kenya, Uganda	Goodlife Pharmacy, PROPARCO	France





- Strengthen the capacities of Egyptian companies as a regional hub for vaccine and biologicals manufacturing and export
- Enhance pharmaceutical strategies and regulations to support Egypt as a regional hub

Project title	Dimension	Partners	Funders
Twinning with Egyptian Drug Authority	Enabling environment	Egyptian Drug Authority, local manufacturers, HISP Facility, WHO	EU
Technical assistance for the development of National Strategy for Vaccines and Biologicals	Enabling environment	Egyptian Ministry of Health and Population, Egyptian Drug Authority, Unified Purchasing Authority, Egyptian Federation of Industries, FWC	EU
Contribution Agreement to support local manufacturers	Enabling environment	Local manufacturers, WHO	EU





- Strengthen Ghana Food and Drugs Authority (FDA) as Regional Center of Regulatory Excellence (RCORE) in vaccine regulatory oversight
- Boost local manufacturing and offtake mechanisms
- Support R&D and promoting technology transfer

Project title	Dimension	Partners	Funders
Program for sustainable economic development in Ghana	Demand Enabling environment Supply	Ghana Food and Drugs Authority, Presidential Vaccine Manufacturing Committee (VMC), National Vaccine Institute, private sector, other Ghanaian health-related stakeholders, GIZ	EU, Germany
PharmaVax	Enabling environment	Ghana Ministry of Trade and Industry (MoTI), Ghana National Vaccine Institute (NVI), Ghana Food and Drugs Authority (), Research Institutions, Kina Foundation, private sector, Government of Ghana, GIZ, WHO	EU, Germany
Remodelling and Equipping of an existing space into Molecular Biology Laboratory for the Ghana FDA in Support of Lot Release of Vaccines and General Capacity for Local Manufacture of Pharmaceuticals	Enabling environment	Ghana Food and Drugs Authority	EU
Support the coordination function of National Vaccine Institute	Enabling environment	NVI (National Vaccine Institute)	EU
WHO Strengthening Local production of vaccines and medicines for improved access in Ghana	Supply	Ghana Ministry of Health and its agencies including the National Vaccine Institute, Food and Drugs Authority, Ghana Health Service (research institutions), private sector (manufacturers), academia in partnership with the EU, WHO	EU, WHO
COVID-19 essential API manufacturing in Africa - Investment into DEK Vaccines Limited	Supply	DEK Vaccines Limited	EU





- Support to the development of the National Plan for Vaccine Research and Development and Local Production 2024-2034
- Invest in local production of pharmaceutical ingredients
- Enhance Nigeria's pharmaceuticals ecosystem and market efficiency

Project title	Dimension	Partners	Funders
Special Measure - Nigeria	Demand Enabling environment	National Institute for Pharmaceutical Research and Development (NIPRD), Government of Nigeria, UNICEF	EU
Access to finance and private sector engagement	Enabling environment	Government of Nigeria, Private sector	EU
Investment into EMZOR for active pharmaceutical ingredients, including antimalarial drugs	Supply	Emzor Pharmaceutical Industries Ltd, European Investment Bank (EIB)	EU
CLOSED: Support to National Institute for Pharmaceutical Research and Development (NIPRD)	Demand Enabling environment Supply	National Institute for Pharmaceutical Research and Development (NIPRD)	EU, Bulgaria





- Support regulatory strengthening for lifesaving, quality products
- Boost skills and jobs
- Foster research and innovation

Project title	Dimension	Partners	Funders
MAV+1 and 2 Rwanda	Enabling environment	Rwanda Food and Drug Authority, Enabel	EU, Belgium
Job partnership and SME support (with component: Skills Development for the pharmaceutical industry)	Enabling environment	Ministry of Trade and Industry, Ministry of Education, Office of the President, Rwanda Food and Drug Authority, GIZ	Germany
Supporting the development of the Rwandan pharmaceutical and biotechnology sector	Enabling environment	Ministry of Trade and Industry, Ministry of Education, Office of the President, Rwanda Food and Drug Authority, GIZ	Germany
Strengthening TVET and Entrepreneurship for the Pharmaceutical and Biotechnological Sector in Rwanda	Enabling environment	Rwanda Ministry of Health, Rwanda Medical Supply, University of Rwanda, GIZ	EU, Germany
Research & Development and developing Skills (RDS) in Rwanda for manufacturing and access to vaccines, medicines, and health technologies	Enabling environment	Ministry of Education (Mineduc), Ministry of Health (MoH), Higher Education Council (HEC), Rwanda TVET Board (RTB), University of Rwanda (College of Science and Technology and College of Medicine and Health Sciences), Rwanda Polytechnic (RP), Rwanda Biomedical Center (RBC), Expertise France	EU
<u>Vaccine Research and Development</u> <u>Capacity in Rwanda</u>	Enabling environment	University of Rwanda, Rwanda Biomedical Center, Butare National Referral Hospital, Swedish International Development Cooperation Agency (SIDA)	EU



# **Rwanda**

Project title	Dimension	Partners	Funders
Access to quality health products in Rwanda	Enabling environment	Rwanda Medical Supply Ltd, Ministry of Health, Rwanda Food and Drug Authority, Health facilities in four districts, Enabel	EU
<u>Twinning Rwanda</u>	Enabling environment	Rwanda Food and Drug Authority, Consortium of national regulatory authorities (France, Germany, Belgium, Lithuania) and agencies from other EU Member States (Austria, Sweden and Greece)	EU
Investment into Akagera Medicines Ltd	Supply	Akagera Medicines Ltd	EU



# Senegal

- Direct investments in local production
- Support the new regulatory body
- Fast-tracking pharmaceutical sector reforms

Project title	Dimension	Partners	Funders
Strengthening vaccine and pharmaceutical production in Senegal / Support the implementation of Senegal's pharmaceutical industry revival plan	Demand Enabling environment Supply	Senegal Ministry of Health, Senegal Ministry of Economy, Senegal national regulatory authority, Institut Pasteur de Dakar (IPD), Enabel, Expertise France, GIZ	EU, France, Germany
Support of local vaccine production in Senegal / 2nd Sectoral budget financing Strengthening of local vaccine production	Demand Enabling environment Supply	Institut Pasteur de Dakar, Senegal Ministry of Economy (MEPC), Senegal Ministry of Health (MSAS), KfW	EU, France, Germany
CLOSED: Support to vaccine manufacturing enabling environment in Senegal, as regional hub in ECOWAS	Demand Enabling environment	Senegal Ministry of Health, Institut Pasteur de Dakar, MEPC, national regulatory authority, GIZ	Germany
Support for the revival of the pharmaceutical industry in Senegal and regulatory strengthening, governance and local supply chain	Enabling environment	Senegal Ministry of Health, Agency of Pharmaceutical Reglementation (ARP)	Belgium
Technical assistance to the Delivery Unit	Enabling environment	Senegal National Regulatory Authority, Senegal Ministry of Health	EU
Technical assistance BIOS Program	Enabling environment	Senegal Ministry of Health, Expertise France	France
Program coordinator mRNA Vaccine	Enabling environment	Senegal Ministry of Health, Expertise France	France





# Senegal

Project title	Dimension	Partners	Funders
Advisor "surveillance épidémiologique, épigénétique et génomique / une seule santé" and Advisor "santé publique, surveillance des vaccins et promotion de la vaccination"	Enabling environment Supply	Senegal Ministry of Health, Expertise France	France
CLOSED: <u>Project AFRICAMARIL</u>	Supply	Institute Pasteur of Dakar, AFD (French Development Agency)	France
CLOSED: <u>MADIBA project</u>	Supply	Senegal Ministry of Finance, Institute Pasteur of Dakar, EIB, European Commission	EU
CLOSED: MADIBA feasibility study and seed funding for equipment	Supply	Institute Pasteur of Dakar, AFD (French Development Agency)	France



# **South Africa**

- Support local vaccine production through the WHO / MPP mRNA technology transfer hub and vaccine production line at Biovac
- Contribute to the continental regulatory system strengthening
- Special support for an enabling environment for regional production

Project title	Dimension	Partners	Funders
Vaccines for Africa - Roll-out and Production in South Africa (SAVax)	Demand  Enabling environment  SAHPRA, DSI-DoH, GIZ		EU, Germany
WHO mRNA Tech Transfer Program (Afrigen) (including support to South African Medical Research Council and Medicines Patent Pool)	Demand Enabling environment Supply	mRNA Tech Transfer Programme, south African Medical Research Council, WHO	
Investment into Biovac multi-vaccine	Demand Supply	Biovac, EIB	EU, France
Centre of Excellence for Strengthening Health Products Safety Monitoring across Southern African countries (CoE4SM)	Enabling environment	Scientific community, regulatory authorities in Southern Africa, Institute of Tropical Medicine (ITM) Antwerp, University of Western Cape	EU, Belgium
Support the enabling environment through a "Biomanufacturing Workforce Development Hub" implemented by KfW (BIOcapSA)	Enabling environment	The Council for Scientific and Industrial Research (CSIR), KfW	EU, Germany
Investment into Aspen Pharmaceuticals	Supply	Aspen Pharmaceuticals, DEG (German Investment Corporation), BIO (Belgian Investment Company for Developing Countries), International Finance Corporation (IFC), PROPARCO	Belgium, France, Germany



# **Additional countries**

Project title	Dimension	Country / Region	Partners	Funders
PSSR 2 Component 2	Enabling environment	Ivory Coast	National regulatory authority, French Development Agency (AFD)	France
Institutional Support Project for the Health Sector Support Program 1, 2 and 3	Enabling environment	Mauritania	Ministry of Health, Enabel	EU, France
CLOSED: Technical assistance Health project and VGB and IP Project	Enabling environment	Central African Republic	French Development Agency (AFD), Expertise France	France
CLOSED: Technical assistance CR	Enabling environment	Ivory Coast	National regulatory authority, Expertise France	France
Programmatic budget funding for the supply chain	Supply	lvory Coast	Ministry of Health, national regulatory authority, French Development Agency (AFD)	France